MORE►
Alpha Cognition
[Image: sudok1/istockphoto]
Alpha Cognition’s ZUNVEYL Receives FDA Approval to Treat Alzheimer’s Disease
by Lance Murray | Jul 29, 2024
“The approval of ZUNVEYL is a pivotal moment in the fight against Alzheimer's disease as it's only the second oral AD treatment to be approved in more than a decade," said CEO Michael McFadden of Alpha Cognition. Based in Vancouver with an office in Frisco, the company was honored at the 2023 BioNTX iC3 Summit as one of eight "Rising Stars."
by David Seeley |
Dec 13, 2023
Based in Vancouver with a North Texas office in Frisco, Alpha Cognition said its novel oral tablet ALPHA-1062 is designed for the treatment of people with mild to moderate Alzheimer's disease. The company was honored at the recent BioNTX iC3 Summit as one of eight "Rising Stars."
MORE►
by Quincy Preston |
Sep 14, 2023
The North Texas bioscience organization, a driving force for growth in the regional ecosystem, will convene leaders at its flagship conference to catalyze industry opportunities, spotlight emerging companies, and make connections.
See who made this year's Rising Stars list—and how you can attend the summit.
See who made this year's Rising Stars list—and how you can attend the summit.
MORE►
